This week, the National Advisory Committee on Immunization recommended that AstraZeneca not be used on people under the age of 55 due to reports of blood clots in Europeans.
Earlier this month, Wellington-Dufferin-Guelph Public Health quelled worries about the vaccine when it said blood clotting concerns weren’t associated with the batch of vaccines Canada has secured.
This week, myFM News asked the local public health unit if that’s still the case.
Spokesperson, Anna Vanderlaan says it’s currently still the subject of intense scientific research but there does appear to be an extremely rare type of clotting disorder that may be associated with the AstraZeneca vaccine.
Vanderlaan went on to say for those over the age of 55, the benefits of protecting Canadians against COVID-19 outweigh the risks and Public Health encourages residents to get immunized.